CL2017001024A1 - Formulación de buprenorfina inyectable - Google Patents

Formulación de buprenorfina inyectable

Info

Publication number
CL2017001024A1
CL2017001024A1 CL2017001024A CL2017001024A CL2017001024A1 CL 2017001024 A1 CL2017001024 A1 CL 2017001024A1 CL 2017001024 A CL2017001024 A CL 2017001024A CL 2017001024 A CL2017001024 A CL 2017001024A CL 2017001024 A1 CL2017001024 A1 CL 2017001024A1
Authority
CL
Chile
Prior art keywords
buprenorfine
provides
liquid composition
administration
formulation
Prior art date
Application number
CL2017001024A
Other languages
English (en)
Inventor
Fredrik Tiberg
Markus Johnsson
Ian Harwigsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52103459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001024(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of CL2017001024A1 publication Critical patent/CL2017001024A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA UNA FORMULACIÓN LIQUIDA INYECTABLE QUE COMPRENDE: A) UNA MATRIZ DE LIBERACIÓN CONTROLADA DE LÍPIDOS QUE COMPRENDE AL MENOS 50% DE LÍPIDOS TRIACILO; AL MENOS UN OXIGENO QUE CONTIENE DISOLVENTE ORGÁNICO; POR LO MENOS 16% EN PESO DE AL MENOS UN AGENTE ACTIVO SELECCIONADO DE BUPRENORFINA Y SALES DE LA MISMA, CALCULADO COMO BASE LIBRE DE BUPRENORFINA. LA INVENCIÓN PROPORCIONA ADEMÁS UNA COMPOSICIÓN DE LIBERACIÓN CONTROLADA, FORMADA POR  LA ADMINISTRACIÓN DE DICHA COMPOSICIÓN LIQUIDA INYECTABLE A UN SUJETO PREFERIBLEMENTE HUMANO. LA INVENCIÓN PROPORCIONA TAMBIÉN UN MÉTODO DE ADMINISTRACIÓN DE BUPRENORFINA A UN SUJETO QUE COMPRENDE INYECTAR DICHA COMPOSICIÓN LIQUIDA Y UN MÉTODO PARA EL TRATAMIENTO DEL DOLOR, PARA TERAPIA DE MANTENIMIENTO DE OPIOIDES O PARA EL TRATAMIENTO DE LA DEPENDENCIA DE OPIOIDES POR MEDIO DE DESINTOXICACIÓN Y/O MANTENIMIENTO O PARA EL TRATAMIENTO O PROFILAXIS DE LOS SÍNTOMAS DE ABSTINENCIA DE OPIOIDES Y/O ABSTINENCIA DE LA COCAÍNA INYECTANDO DICHA COMPOSICIÓN LÍQUIDA.</p>
CL2017001024A 2014-10-27 2017-04-25 Formulación de buprenorfina inyectable CL2017001024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1419091.2A GB201419091D0 (en) 2014-10-27 2014-10-27 Formulations

Publications (1)

Publication Number Publication Date
CL2017001024A1 true CL2017001024A1 (es) 2017-11-10

Family

ID=52103459

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001024A CL2017001024A1 (es) 2014-10-27 2017-04-25 Formulación de buprenorfina inyectable

Country Status (17)

Country Link
US (2) US20180015031A1 (es)
EP (1) EP3212168A1 (es)
JP (1) JP6768648B2 (es)
KR (2) KR20170072237A (es)
CN (1) CN107205920B (es)
AU (1) AU2015340661B2 (es)
BR (1) BR112017008721A2 (es)
CA (1) CA2964045C (es)
CL (1) CL2017001024A1 (es)
EA (1) EA033935B1 (es)
GB (1) GB201419091D0 (es)
IL (1) IL251413B2 (es)
MX (1) MX2017005461A (es)
MY (1) MY183540A (es)
SG (1) SG11201703158WA (es)
TW (1) TW201625250A (es)
WO (1) WO2016066655A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014016428A1 (en) 2012-07-26 2014-01-30 Camurus Ab Opioid formulations
WO2016071767A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
WO2018060212A1 (en) 2016-09-27 2018-04-05 Camurus Ab Mixtures and formulations comprising an alkyl ammonium edta salt
HRP20230062T8 (hr) * 2016-09-13 2023-04-14 Alar Pharmaceuticals Inc. Formulacije buprenorfina sa produženim oslobađanjem
PT3512495T (pt) 2016-09-15 2023-02-15 Camurus Ab Formulações análogas a prostaciclina
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
TWI819756B (zh) * 2021-08-20 2023-10-21 大陸商蘇州恩華生物醫藥科技有限公司 包含塞納布啡的藥物組合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
EP1422230B1 (en) * 2002-11-25 2007-12-26 Chi Mei Foundation Medical Center Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions
DE602005008247D1 (de) * 2004-06-04 2008-08-28 Camurus Ab Flüssige depotformulierungen
MX2011000629A (es) * 2008-07-17 2011-04-26 Merial Ltd Formulaciones analgesicas inyectables de larga duracion para animales.
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
WO2014016428A1 (en) * 2012-07-26 2014-01-30 Camurus Ab Opioid formulations
CN103142458B (zh) * 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法

Also Published As

Publication number Publication date
EA201790721A1 (ru) 2017-09-29
CA2964045A1 (en) 2016-05-06
MY183540A (en) 2021-02-25
NZ730521A (en) 2023-11-24
KR20170072237A (ko) 2017-06-26
MX2017005461A (es) 2018-01-17
IL251413A0 (en) 2017-05-29
IL251413B2 (en) 2023-05-01
JP6768648B2 (ja) 2020-10-14
US20210308041A1 (en) 2021-10-07
GB201419091D0 (en) 2014-12-10
CN107205920A (zh) 2017-09-26
SG11201703158WA (en) 2017-05-30
EA033935B1 (ru) 2019-12-11
EP3212168A1 (en) 2017-09-06
CN107205920B (zh) 2021-05-25
KR20230039767A (ko) 2023-03-21
AU2015340661A1 (en) 2017-04-20
TW201625250A (zh) 2016-07-16
US20180015031A1 (en) 2018-01-18
AU2015340661B2 (en) 2018-04-26
KR102541281B1 (ko) 2023-06-13
CA2964045C (en) 2023-03-07
WO2016066655A1 (en) 2016-05-06
JP2017532354A (ja) 2017-11-02
IL251413B1 (en) 2023-01-01
BR112017008721A2 (pt) 2018-01-30

Similar Documents

Publication Publication Date Title
CL2017001024A1 (es) Formulación de buprenorfina inyectable
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CO2018002060A2 (es) Compuestos farmacéuticos
ECSP17002135A (es) Compuestos antiproliferativos y métodos de uso de los mismos
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
MX2016004035A (es) Formulaciones de espiro-isoxazolina de accion prolongada.
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CO2017002268A2 (es) Inhibidores espirocíclicos de catepsina c
CL2020000747A1 (es) Formulaciones de niraparib.
CO7190238A2 (es) Formulaciones de opioides
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2017001539A1 (es) Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
CY1124016T1 (el) Φαρμακοτεχνικες μορφες οπιοειδων